iRhythm Technologies, Inc. (IRTC)
Juste valeurFondamental
43
Prix
$111.51
Capitalisation boursière
$3.75B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with BioIS to develop and commercialize pulse oximetry, accelerometry, and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring products and services. The company was formerly known as iRhythm Technologies, Inc. and changed its name to iRhythm Holdings, Inc. in January 2026. iRhythm Holdings, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 18 septembre 2026 with claude-haiku-4-5 — shared with all users
Its Preventice Solutions arm, acquired for $925 million, is the closest challenger to Zio in long-term continuous ECG patch monitoring in the United States.
Baxter owns Bardy Diagnostics, whose Carnation ambulatory monitor patch is prescribed for the same arrhythmia work-ups that Zio is used for.
GE HealthCare supplies the traditional 24-to-48-hour Holter monitors that hospitals and clinics can choose instead of sending a patient home with a Zio patch.
Through BioTelemetry, which it bought for $2.8 billion, Philips sells the wearable ECG patches and mobile cardiac telemetry services that compete directly with iRhythm's Zio for the same cardiologists and the same insurance reimbursement.
Medtronic's LINQ family of insertable cardiac monitors targets the same patients under investigation for atrial fibrillation and unexplained fainting, competing for the diagnostic referral before a Zio is ever prescribed.
This private US company sells the VitalPatch, a disposable ECG patch with AI arrhythmia detection sold to the same cardiology practices that buy Zio.
Bilan & Liquidités
Chiffre d'affaires
$825M
12 derniers mois (au 30/06/2026)
Résultat net
$-14M
12 derniers mois (au 30/06/2026)
Flux de trésorerie libre
$35M
Capitaux propres totaux
$153M
Passif total
$867M
Ratio de liquidité général
3.85
Couverture des intérêts
1.89
Dette/EBITDA
-
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$104.37
Prix actuel
$111.51
Marge de sécurité
-6.8%
Fourchette de juste valeur
$67.84 - $140.89
Écart entre les méthodes de valorisation utilisées, pas un intervalle de confiance calibré statistiquement.
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
-
ROE
-29.2%
Ratio P/B
20.14
P/FCF
96.12
Marge brute
71.5%
ROIC
-2.2%
Radar de rentabilité
Création de valeur (avantage concurrentiel)
ROIC
-2.2%
WACC
10.5%
ROIC − WACC
-12.7 pp
Le ROIC est inférieur au coût du capital — l'entreprise détruit de la valeur pour chaque dollar investi.
Critères d'analyse fondamentale
Réussi (12)
- EPS shows upward trend
- Price CAGR 14.06%
- Gross Margin 71.5%
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Low reliance on intangibles
- Revenue Growth 5Y 23.0%
- Analyst Consensus 95% Buy
- Earnings Surprise avg 3463.2%
- Net Margin Trend -1.7% vs -14.1%
- Piotroski F-Score 6/9
Échoué (10)
- ROIC -2.2%
- P/FCF 96.12
- P/B Ratio 20.14
- Debt/Equity ratio
- Operating Margin -3.0%
- CapEx intensity
- Return on Tangible Assets
- DCF valuation (Overvalued)
- ROE -9.0%
- Share Dilution 2.7%
Indisponible (5)
- Dividend Payout NaN%
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Score F de Piotroski
Signaux mixtes : certains domaines nécessitent attention
Qualité des bénéfices
Qualité faible : examiner la comptabilité
Dilution du capital
Émission de nouvelles actions, diluant la participation
Participations institutionnelles
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Mr. Quentin S. Blackford | President, CEO & Director | 46 |
| Mr. Daniel G. Wilson | CFO & Principal Financial Officer | 43 |
| Dr. Minang P. Turakhia M.D., M.S. | Chief Medical & Scientific Officer and Executive VP of Advanced Technologies | 51 |
| Mr. Patrick Michael Murphy J.D. | Chief Business & Legal Officer | 46 |
| Mr. Chad M. Patterson | Chief Commercial and Product Officer | 43 |
| Mr. Mervin Smith | Executive Vice President of Business Operations | 50 |
| Mr. Marc Rosenbaum | Senior VP of Finance & Chief Accounting Officer | 52 |
| Mr. Brian Lawrence | Executive VP & CTO | 55 |
| Ms. Lisa Pecora | Senior Vice President of Finance & Investor Relations | - |
| Mr. Sean Clinton Freeman | Executive Vice President of Strategy & Corporate Development | 49 |
Risque d'audit
9
Risque du conseil
5
Risque de rémunération
3
Risque droits des actionnaires
7
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Documents
- Voir le document
Rapport annuel (10-K)
Un aperçu annuel de l'activité, des résultats financiers et des risques de l'entreprise.
Déposé le 2026-02-19
- Voir le document
Rapport trimestriel (10-Q)
Une mise à jour de la performance financière des trois derniers mois.
Déposé le 2026-08-06
- Voir le document
Rapport d'événement important (8-K)
Un avis concernant un événement important, comme un changement de direction ou une annonce majeure.
Déposé le 2026-09-22
via SEC EDGAR
Historique des résultats
via SEC EDGAR
Latest News
Recent headlines for IRTC, sourced from Markets Gazette.
- 3d agoPOSITIVEJP Morgan forecasts a 20x revenue increase for this AI stock
JP Morgan has significantly boosted its outlook for US-listed iRhythm Technologies Inc. (IRTC), forecasting a remarkable 20-fold increase in the company's revenue by 2030. This optimistic projection is underpinned by the escalating demand for computing power and a concurrent rise in the pricing power of 'neocloud' companies like iRhythm. In a September note, the bank upgraded IRTC from 'Underweight' to 'Overweight', signaling strong conviction in its future growth trajectory. Investors should monitor iRhythm's ability to capitalize on this burgeoning market, as the forecast suggests substantial upside potential.
- 6/16/2026NEGATIVEiRhythm Investigates Cyber Incident After Hackers Claim Access To Sensitive Data
iRhythm Technologies is investigating a cybersecurity incident where hackers claim to have accessed sensitive patient and proprietary data. The breach reportedly occurred via third-party applications. While the company states it does not foresee a material impact on its operations or finances, any data breach involving patient information can lead to regulatory scrutiny, reputational damage, and potential legal liabilities. Investors will monitor the situation closely for any further developments or undisclosed consequences that could affect the company's long-term prospects and stock valuation.
via Markets Gazette